Richard A. Larson to Blast Crisis
This is a "connection" page, showing publications Richard A. Larson has written about Blast Crisis.
Connection Strength
0.389
-
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia. 2012 May; 26(5):959-62.
Score: 0.104
-
Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1). Leukemia. 2003 Apr; 17(4):691-9.
Score: 0.057
-
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002 May 15; 99(10):3530-9.
Score: 0.054
-
Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia. Leukemia. 1996 May; 10(5):795-802.
Score: 0.035
-
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies. Cancer Chemother Pharmacol. 1995; 36(3):204-10.
Score: 0.032
-
Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study. Am J Hematol. 1993 Aug; 43(4):286-90.
Score: 0.029
-
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2013 May 02; 121(18):3703-8.
Score: 0.028
-
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 Jun 17; 362(24):2251-9.
Score: 0.023
-
Association of a chromosomal 3;21 translocation with the blast phase of chronic myelogenous leukemia. Blood. 1987 Nov; 70(5):1338-42.
Score: 0.020
-
Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11). Genes Chromosomes Cancer. 1990 Jul; 2(2):147-58.
Score: 0.006